Skip to main content
OpenTrials

Clinical trial condition

Alpha1-Antitrypsin Deficiency

Explore clinical trials studying Alpha1-Antitrypsin Deficiency. Study availability and eligibility vary by location and protocol.

13 public trials 3 recruiting studies
Refine in advanced search Browse all conditions

Alpha1-Antitrypsin Deficiency trial results

Recruiting

A Study in Adults to Learn About Inherited Alpha-1 Antitrypsin Deficiency (AATD) and AATD Related Liver Problems

NCT06512454

Conditions
Alpha1-Antitrypsin Deficiency, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Digestive System Diseases, +9 more
Locations
  • University of Florida Gainesville, Florida, United States
  • University of South Carolina Charleston, South Carolina, United States
  • Vanderbilt University Medical Center Nashville, Tennessee, United States
  • Vienna General Hospital (AKH Wien) Vienna, Austria
View Trial Details
Recruiting

Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin Protein

NCT05677971

Conditions
Alpha1-Antitrypsin Deficiency, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Digestive System Diseases, +9 more
Locations
  • University of Alabama at Birmingham Birmingham, Alabama, United States
  • St. Joseph's Hospital and Medical Center Phoenix, Arizona, United States
  • Mayo Clinic Phoenix, Arizona, United States
  • University of Arizona Thomas D. Boyer Liver Institute Tucson, Arizona, United States
View all 89 locations
View Trial Details
Recruiting

Study to Learn About the Safety of Fazirsiran and if it Can Help People With Alpha-1 Antitrypsin Liver Disease With Mild Liver Scarring (Fibrosis)

NCT06165341

Conditions
Alpha1-Antitrypsin Deficiency, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Digestive System Diseases, +9 more
Locations
  • St Joseph's Hospital and Medical Center Phoenix, Arizona, United States
  • Mayo Clinic - PPDS Phoenix, Arizona, United States
  • University of Arizona Thomas D. Boyer Liver Institute Tucson, Arizona, United States
  • University of California San Diego La Jolla, California, United States
View all 41 locations
View Trial Details
Completed

A Study to Evaluate Safety, Tolerability and Pharmacokinetics of Two Different Doses of Alpha1-Proteinase Inhibitor Subcutaneous (Human) 15% in Participants With Alpha1-Antitrypsin Deficiency

NCT04722887

Conditions
Alpha1-Antitrypsin Deficiency, Chronic Disease, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, +14 more
Locations
  • UCLA Medical Center Los Angeles, California, United States
  • University of Florida Gainesville, Florida, United States
  • University of Miami Miami, Florida, United States
  • Cleveland Clinic Cleveland, Ohio, United States
View Trial Details
Completed

Evaluation of the Efficacy and Safety of VX-864 in Subjects With the PiZZ Genotype

NCT04474197

Conditions
Alpha1-Antitrypsin Deficiency, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Digestive System Diseases, +9 more
Locations
  • University of Alabama at Birmingham Birmingham, Alabama, United States
  • David Geffen School of Medicine at UCLA Los Angeles, California, United States
  • University of California Davis Medical Center Sacramento, California, United States
  • National Jewish Health Denver, Colorado, United States
View all 30 locations
View Trial Details
Completed

GLASSIA Safety, Immunogenicity, and Bronchoalveolar Lavage Study

NCT02525861

Conditions
Alpha1-Antitrypsin Deficiency, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Digestive System Diseases, +9 more
Locations
  • Arizona Board of Regents, University of Arizona Tucson, Arizona, United States
  • UCLA Medical Center Los Angeles, California, United States
  • Cedars Sinai Medical Center, Division of Pulmonary and Critical Care Medicine Los Angeles, California, United States
  • University of California Davis Health System Sacramento, California, United States
View all 18 locations
View Trial Details
Completed

GLASSIA Infusion Rate Study

NCT01651351

Conditions
Alpha1-Antitrypsin Deficiency, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Digestive System Diseases, +11 more
Locations
  • Overland Park, Kansas, United States
View Trial Details

Related conditions